Lantern Pharma Inc.
Organization details
- Legal name
- Lantern Pharma Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Texas
- Headquarters city
- Dallas
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LTRN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001763950
- EIN
- 46-3973463
Board of directors
-
D. Jeffrey Keyser · DirectorSince 2024
-
David S. Silberstein · DirectorSince 2024
-
Lee Troy Schalop · DirectorSince 2025
-
Maria-Luisa Maccecchini · DirectorSince 2024
-
Panna Sharma · Director · President & CEOSince 2024
-
Vijay Chandru · DirectorSince 2024
Chief executives
Director election results
Annual meeting of September 19, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
98.0%
-
98.5%
-
98.5%
-
98.5%
-
98.5%
-
98.6%
Board connections
1 of this board's directors also sit on 1 other board. 1 is in the same sector.
-
Annovis Bio Inc. Same sectorvia Maria-Luisa Maccecchini
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $200,001
- 2 purchases by 2 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 12, 2026 | Lee Troy Schalop Director | Open-market purchase | +48,544 | $2.06 | $100,001 |
| May 12, 2026 | D. Jeffrey Keyser Director | Open-market purchase | +48,544 | $2.06 | $100,001 |
| Jun 13, 2025 | BIOS Fund II QP, LP 10% owner | Open-market sale | −7,206 | $3.09 | $22,267 |
| Jun 13, 2025 | BP Directors, LP 10% owner | Open-market sale | −7,206 | $3.09 | $22,267 |
| Jun 13, 2025 | BIOS Fund II QP, LP 10% owner | Open-market sale | −12,319 | $3.09 | $38,066 |
| Jun 13, 2025 | BP Directors, LP 10% owner | Open-market sale | −12,319 | $3.09 | $38,066 |
| Jun 13, 2025 | BIOS Fund II QP, LP 10% owner | Open-market sale | −1,903 | $3.09 | $5,880 |
| Jun 13, 2025 | BP Directors, LP 10% owner | Open-market sale | −1,903 | $3.09 | $5,880 |
| Jun 13, 2025 | BIOS Fund II QP, LP 10% owner | Open-market sale | −14,218 | $3.09 | $43,934 |
| Jun 13, 2025 | BP Directors, LP 10% owner | Open-market sale | −14,218 | $3.09 | $43,934 |
| Jun 13, 2025 | BIOS Fund II QP, LP 10% owner | Open-market sale | −4,354 | $3.09 | $13,454 |
| Jun 13, 2025 | BP Directors, LP 10% owner | Open-market sale | −4,354 | $3.09 | $13,454 |
| Jun 12, 2025 | BIOS Fund I, LP 10% owner | Open-market sale | −10,925 | $3.38 | $36,927 |
| Jun 12, 2025 | Cavu Advisors, LLC 10% owner | Open-market sale | −10,925 | $3.38 | $36,927 |
| Jun 12, 2025 | BIOS Fund I, LP 10% owner | Open-market sale | −18,678 | $3.38 | $63,132 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Lantern Pharma Inc.
Who is the CEO of Lantern Pharma Inc.?
Panna Sharma is Lantern Pharma Inc.'s President and CEO.
How many directors are on Lantern Pharma Inc.'s board?
Lantern Pharma Inc.'s board has 6 directors: D. Jeffrey Keyser, David S. Silberstein, Lee Troy Schalop, Maria-Luisa Maccecchini, Panna Sharma and Vijay Chandru.
Are Lantern Pharma Inc. insiders buying or selling shares?
Over the last 12 months, Lantern Pharma Inc. insiders bought $200,001 of shares in 2 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="lantern-pharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.